Slide 1: Aroa Biosurgery Half Year Update October 2022
For personal use only AROA BIOSURGERY (ARX) HALF YEAR UPDATE OCTOBER 2022 Unlocking regenerative healing for everybody
Slide 2: Important Notice and Disclaimer
|2 Important Notice and Disclaimer This presentation (Presentation) is dated 25 October 2022 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AROA or the Company). For personal use only Information in this Presentation The information in this Presen
Slide 3: AROA at a Glance
|3 AROA at a Glance Well established high-growth soft tissue regeneration company For personal use only Four product AROA ECM™ platform families for new products, line extensions >US$2.5b2 TAM predominantly sold to US & enables AROA’s “dead-space” NPWT platform for existing products hospitals US Dir
Slide 4: Substantial Growth Opportunities > $2.5B TAM
Substantial Growth Opportunities > $2.5B1 TAM For personal use only Complex Wounds Soft Tissue Reconstruction Total Addressable Market Total Addressable Market > $1.4B2 USD > $1.3B3 USD e.g. Diabetic Foot Ulcers, e.g. Trauma, tumour removal, e.g. Hernia repair, abdominal Venous Ulcers, Pressure Ulce
Slide 5: AROA ECM – Structure & Biology for Regenerative Healing
|5 AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach with proven tissue regeneration properties across multiple products1-6 For personal use only 1. Irvine, S. M., et al. (2011). "Quantification of in vitro and in vivo angiogenes
Slide 6: H1 FY23 Half Year Results
|6 H1 FY23 Half Year Results1 For personal use only Product Sales Myriad sales Product Gross Margin NZ$28.8m NZ$5.6m 44% constant currency2 84% 242% constant currency vs. guidance of 77%3 growth on pcp growth on pcp Normalised4 EBITDA FOREX tail winds positive contribution Cash balance positive (~NZ
Slide 7: Myriad
|7 Myriad For personal use only Ongoing field salesforce expansion: 35 targeting ~41 by end of FY23. Salesforce productivity: positive operational trends with anticipated gains from line extensions & Symphony launch. Myriad - MASTRR Clinical Registry: 97 patients recruited, 3 sites - targeting 300 p
Slide 8: Symphony
|8 Symphony Disruptive US reimbursement changes proposed For personal use only for ‘Skin Substitutes’ from CY23:1 Draft changes include moving to site-neutral fixed payment, incentives to favor products with high efficacy at a reasonable price & fewer applications during an episode of care. Under pu
Slide 9: OviTex & OviTex PRS
|9 OviTex & OviTex PRS For personal use only OviTex, OviTex LPR & PRS continue to gain momentum: TELA Bio™ sales guidance of US$42- 45m in CY22 up from US$29.5m in CY21.1 Bravo I (ventral hernia): 92 enrolled patients, 2.6% recurrence rate in ventral hernias at 24- months.2 ReBAR (robotic ): 157 ing
Slide 10: Endoform
| 10 Endoform For personal use only Modest growth: serviced by virtual inside sales team. Clinical evidence: Targeting completion of Venous Leg Ulcer real-world study by Mar ’23.
Slide 11: Enivo
| 11 Enivo For personal use only US FDA 510k submission: Nov ’22. US Total Pre-clinical model demonstrates efficacy Addressable potential: Peer-reviewed publication Oct ’22.1 Market >$1B (AROA management Set-up for pilot clinical study: 10 patients in estimate) Mastectomy H1 CY23. Platform technolog
Slide 12: FY23 Updated Guidance
| 12 FY23 Updated Guidance1 For personal use only Forecast Product Sales Forecast Product Gross Normalised EBITDA3 Margin NZ$60-62m2 ~breakeven Total revenue of NZ$62-64M 84% Cash Balance ~NZ$50m 1. Given the dynamic and evolving impact of COVID-19, all forward looking statements in relation to FY23
Slide 13: FY23 Catalysts & Milestones
| 13 FY23 Catalysts & Milestones For personal use only Post-COVID AROA Sales Symphony Product Momentum Launch COVID-19 expected to have a reduced impact for remainder of FY23 Disruptive potential reimbursement Fully dedicated changes, clinical outcomes & cost field sales team. Myriad expected to sav
Slide 14: Contacts
CONTACTS For personal use only Simon Hinsley Matt Wright Sarah Tora Investor Relations Media Corporate Communications Manager m +61 401 809 653 m +61 451 896 420 m +64 21 531 043 shinsley@aroabio.com matt@nwrcommunications.com.au sarah.tora@aroabio.com Visit our website www.aroabio.com and find us o